Gareth Morgan

Dr. Gareth Morgan

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 March 2007 in Journal of Molecular Biology
Verified
Journal Article
Closed access
SKSaša Jenko Kokalj
Saša Jenko Kokalj
GGGregor Gunčar
Gregor Gunčar
IŠIgor Štern
Igor Štern
GMGareth Morgan
Gareth Morgan
SRSabina Rabzelj
Sabina Rabzelj
DTDusan Turk
Dusan Turk

25 August 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CCChristina Cooley
Christina Cooley
LRLisa M. Ryno
Lisa M. Ryno
LPLars Plate
Lars Plate
GMGareth Morgan
Gareth Morgan
JHJohn Hulleman
John Hulleman
RWR. Wiseman
R. Wiseman
Significance: Light-chain amyloidosis (AL) is a devastating human disease involving the clonal expansion of a plasma cell and the secretion of destabilized, amyloidogenic immunoglobulin light chains (LCs). Secreted amyloidogenic LCs aggregate extracellularly, leading to proteotoxicity on distal tissues. Available therapeutic strategies to treat AL specifically target the cancerous plasma cell population. While this approach is effective in ∼70% of patients, patients who present with substantial LC-related organ proteotoxicity are generally too sick to tolerate standard chemotherapeutics. Here, we show that stress-independent activation of unfolded protein response-associated transcription factors selectively reduces secretion of amyloidogenic LCs and decreases extracellular soluble LC aggregates associated with proteotoxicity in AL. These results identify a promising therapeutic strategy to treat AL patients unserved by current treatments.

10 April 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GMGareth Morgan
Gareth Morgan
NYNicholas L. Yan
Nicholas L. Yan
DMDavid E. Mortenson
David E. Mortenson
EREnrico Rennella
Enrico Rennella
JBJoshua M. Blundon
Joshua M. Blundon
JKJeffery Kelly
Jeffery Kelly
In Ig light-chain (LC) amyloidosis (AL), the unique antibody LC protein that is secreted by monoclonal plasma cells in each patient misfolds and/or aggregates, a process leading to organ degeneration. As a step toward developing treatments for AL patients with substantial cardiac involvement who have difficulty tolerating existing chemotherapy regimens, we introduce small-molecule kinetic stabilizers of the native dimeric structure of full-length LCs, which can slow or stop the amyloidogenicity cascade at its origin. A protease-coupled fluorescence polarization-based high-throughput screen was employed to identify small molecules that kinetically stabilize LCs. NMR and X-ray crystallographic data demonstrate that at least one structural family of hits bind at the LC–LC dimerization interface within full-length LCs, utilizing variable-domain residues that are highly conserved in most AL patients. Stopping the amyloidogenesis cascade at the beginning is a proven strategy to ameliorate postmitotic tissue degeneration.

31 December 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
EREnrico Rennella
Enrico Rennella
GMGareth Morgan
Gareth Morgan
JKJeffery Kelly
Jeffery Kelly
LKLewis E. Kay
Lewis E. Kay
Significance: The misfolding and/or aggregation of proteins can give rise to amyloid diseases, including immunoglobulin light-chain (LC) amyloidosis, leading to large proteinaceous deposits in organs throughout the body. A third of patients die within a year of diagnosis. The LC structure–proteotoxicity relationships and how protein aggregation causes degeneration are not understood. Using solution NMR we characterized the strengths of interactions between different domains in the dimeric 2-domain immunoglobulin LC structure to dissect their relative importance in protecting against aggregation. The constant domain (C L ) is particularly important in conferring protection, as are the stabilities of the individual domains. Our studies establish a threshold of stability, below which aggregation occurs rapidly, suggesting that stabilizing the C L –C L domain interface could prevent aggregation.

1 August 2001 in Analytical Biochemistry
Verified
Journal Article
Closed access
CHCatherine M. Halliwell
Catherine M. Halliwell
GMGareth Morgan
Gareth Morgan
COChung-Pei Ou
Chung-Pei Ou
ACAnthony E.G. Cass
Anthony E.G. Cass